Agah Ramtin purchased $46K of RNXT
Agah Ramtin (Executive Chairman and CMO) purchased 50,000 shares of RenovoRx, Inc. (RNXT) at $0.93 on 2026-11-16.
RenovoRx, Inc.
RenovoRx is a life sciences company that develops targeted oncology therapies and commercializes RenovoCath, an FDA-cleared local drug-delivery device, for use in the United States. Its patented Trans-Arterial Micro-Perfusion (TAMP) platform uses RenovoCath to deliver therapeutic agents across an arterial wall near a tumor. The device is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion and chemotherapeutic drug infusion. RenovoRx sells RenovoCath as a standalone device to cancer centers and is evaluating IAG, a drug-device combination that delivers the chemotherapy gemcitabine through RenovoCath, in a Phase III trial for locally advanced pancreatic cancer. IAG is not approved for commercial sale. The company also conducts post-marketing registry studies and supports investigator-initiated trials in solid tumors. RenovoRx makes money from RenovoCath device sales and explores collaborations and potential out-licensing of IAG and its TAMP platform. It is headquartered in Mountain View, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Agah Ramtin (Executive Chairman and CMO) purchased 50,000 shares of RenovoRx, Inc. (RNXT) at $0.93 on 2026-11-16.
RenovoRx (RNXT) reported Q3 2026 revenue of $1.07M, up 17% QoQ and 300% YoY. It has 26 active commercial cancer centers and expects 36 by year-end. Phase III trial enrollment is complete, with results expected in 2H 2027. The company faces net losses and higher expenses but remains optimistic about growth.
Ascendiant Capital kept its Buy rating on RenovoRx and increased its price target to $15 from $14.50, a 3.4% rise. This implies a 1227.4% upside from the Nov 6 close of $1.13.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning RNXT (RenovoRx, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent RNXT coverage spans earnings, financial news and insider activity.
In the last 30 days, RNXT insiders filed 1 SEC Form 4 transaction — 1 purchase ($46K) and no sales. The most active reporter was Agah Ramtin, Executive Chairman and CMO, with 1 filing.
This is a small open-market insider buy with limited standalone signal; it may modestly support sentiment but is unlikely to drive price by itself.
No new catalyst; the recap is unlikely to move the stock.
Ascendiant Capital kept its Buy rating on RenovoRx and increased its price target to $15 from $14.50, a 3.4% rise. This implies a 1227.4% upside from the Nov 6 close of $1.13.
Management highlights commercial traction (active centers and funnel growth) and reiterates full-year revenue guidance, supporting a constructive near-term demand outlook.
First earnings disclosure for a micro‑cap biotech; modest revenue beat may support short‑term price appreciation.
AlphAI scores every news story that mentions RNXT with an AI model for sentiment and relevance, and aggregates insider trades from RenovoRx, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Agah Ramtin (Executive Chairman and CMO) purchased 50,000 shares of RenovoRx, Inc. (RNXT) at $0.93 on 2026-11-16.
RenovoRx (RNXT) reported Q3 2026 revenue of $1.07M, up 17% QoQ and 300% YoY. It has 26 active commercial cancer centers and expects 36 by year-end. Phase III trial enrollment is complete, with results expected in 2H 2027. The company faces net losses and higher expenses but remains optimistic about growth.
Ascendiant Capital kept its Buy rating on RenovoRx and increased its price target to $15 from $14.50, a 3.4% rise. This implies a 1227.4% upside from the Nov 6 close of $1.13.
RenovoRx (RNXT) reported Q3 2026 earnings, highlighting growth in active commercial cancer centers (26 up from 21) and a robust commercial funnel. The company expects to meet its year-end target of 36 active centers. Revenue guidance remains $3.75M-$4.25M. New account activations and repeat orders are key growth metrics. RenovoCath's use expanded to sarcoma and a neoadjuvant trial, with 10 issued U.S. patents and more pending.
RenovoRx Inc (RNXT) reported Q3 2026 record revenue of $1.07M, up 17% sequentially. CEO Sean Bagai discussed potential impacts of Razin-Q approval on pancreatic cancer treatment and commercialization plans. The company has 26 active commercial centers, with a target of 36 by year-end. Phase III TIGER-PACT trial data is expected in H2 2027. Gross margin was 82%, and cash position is $10.4M. Full-year 2026 revenue guidance remains $3.75M-$4.25M.
RenovoRx, Inc. (RNXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion
RenovoRx (Nasdaq: RNXT) announced the first patient has enrolled in the PRISM-TAMP trial, evaluating its TAMP platform for borderline resectable pancreatic cancer. The trial, sponsored by the University of Vermont, aims to assess tumor regression and safety. RenovoRx reported $1.1M in 2025 RenovoCath sales and $909K in Q2 2026. The company expects topline data from its Phase III TIGeR-PaC trial in late 2027.
RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.
RenovoRx (RNXT) rose 15% to $1.97 on positive Phase 3 trial data. Evolus (EOLS) hit $9.15 after 21% revenue growth. Crinetics (CRNX) reached $85.01 ahead of $10B Vertex (VRTX) acquisition. Apogee (APGE) hit $135.08 before $10.9B AbbVie (ABBV) deal. All hit 52-week highs on August 31, 2026.
Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.